Monday, 17 February 2020

Necessary Instructions for Women to be Prepared Against the Fight With the Dense Breast

High breast density can lead to cancer and this date there is no cure for breast cancer found.

Tips to Consider Before Having Dense Breast Treatment


We all know, high breast density can lead to a deadly disease like cancer.

What are the Treatment for Dense Breast?

Dense breast issue is increasing and so does the increasing hard-work of preventing it and letting people know about the issue. Many people are unaware of the issue and many are trying their level best to let people be aware about the issue. In this blog, we will discuss about the dense breast treatment.

Tuesday, 24 December 2019

Breast Cancer, Treatments & Dense Breast Law One Should Know


Breast cancer is the most frequently diagnosed cancer among women world wide. Breast cancer depends on many factors such a family history, Age. The risk of breast cancer increases with age, Genetics, Dense breast tissue. In which dense breast is considered as the most common cause of breast cancer. Lots of efforts are being done to save the woman from the disease. There may be some concerns and treatment of dense breast you should know such as:-
  • Any family history of breast cancer or breast lumps, consult a doctor have a mammography check
  • Chances of breast cancer increase with age women over 45-50 should do a mammography check cause they have more chance of dense breasts. Talkingabout treatments Mammography is the most common tool which helps to find densebreast tissues. But in the case of higher breast density, radiologist prefer other treatment to find dense breast and causes such as:-
  • Breast MRI
  • Breast Ultrasound
  • 3-D Mammography
  • Tomosynthesis

What Is Dense Breast Law?
On 28th March 2019, Keeping in mind the interest of the patients, FDA announcedits necessary for mammography facilities to include breast density information in reports sent to patients and their physicians. DB-I has analysed the proposed language and submitted comments to the FDA during the designated “open for public comment” period. DB-I comments are available.